Table 1. Baseline Patient Characteristics.
| Characteristic | No. (%) | |
|---|---|---|
| Control arm (n = 51) | Experimental arm (n = 45) | |
| Age, median (IQR), y | 67 (58-74) | 67 (59-75) |
| Sex | ||
| Female | 9 (18) | 11 (24) |
| Male | 42 (82) | 34 (76) |
| Karnofsky Performance Status score | ||
| 100 | 3 (6) | 4 (9) |
| 90 | 17 (33) | 20 (44) |
| 80 | 19 (37) | 17 (38) |
| 70 | 12 (24) | 4 (9) |
| Primary tumor histologic result | ||
| Head and neck squamous cell carcinoma | 11 (22) | 9 (20) |
| Melanoma | 12 (24) | 11 (24) |
| Non–small cell lung carcinoma | 4 (8) | 3 (7) |
| Renal cell carcinoma | 8 (16) | 6 (13) |
| Urothelial carcinoma | 16 (31) | 16 (36) |
| No. of lesions | ||
| ≤3 | 14 (27) | 10 (22) |
| >3 | 37 (73) | 35 (78) |
| American Joint Committee on Cancer stage | ||
| III | 2 (4) | 6 (13) |
| IV | 49 (96) | 39 (87) |
| No. of prior systemic treatment lines | ||
| 0 | 17 (33) | 14 (31) |
| 1 | 23 (45) | 24 (53) |
| ≥2 | 11 (22) | 7 (16) |
| Prior radiotherapy | 28 (55) | 18 (40) |
| Immune checkpoint inhibitor regimen | ||
| Atezolizumab every 3 wk | 6 (12) | 5 (11) |
| Nivolumab every 2 wk | 21 (41) | 21 (47) |
| Nivolumab every 4 wk | 4 (8) | 2 (4) |
| Pembrolizumab every 3 wk | 20 (39) | 17 (38) |
| No. of SBRT-treated lesions | ||
| 1 | NA | 16 (36) |
| 2 | 13 (29) | |
| 3 | 10 (20) | |
| Location of SBRT-treated lesions (n = 69) | ||
| Lymph node | NA | 21 (30) |
| Lung | 23 (33) | |
| Liver | 4 (6) | |
| Bone | 9 (13) | |
| Other | 12 (17) | |
Abbreviations: NA, not applicable; SBRT, stereotactic body radiotherapy.